Cited 0 times in
Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.date.accessioned | 2024-05-30T06:57:26Z | - |
dc.date.available | 2024-05-30T06:57:26Z | - |
dc.date.issued | 2023-08 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/199473 | - |
dc.description.abstract | Background: Advanced or metastatic esophageal squamous cell carcinoma (ESCC) is associated with poor prognosis; new first- line systemic treatment options are needed. Combining immuno-oncology therapies with standard chemo-therapy may represent a promising approach for the treatment of solid tumors. Results from a Phase Ib study evaluating durvalumab with tremelimumab and chemotherapy in patients with advanced or metastatic ESCC are reported.Methods: Adults with advanced or metastatic ESCC who were candidates for first- line platinum- based chemotherapy received durvalumab 1500 mg (Day 1), tremelimumab 75 mg (Day 1), cisplatin 80 mg/m(2) (Day 1) and 5-fluorouracil (5-FU) 800 mg/m(2) (Days 1- 5) in 28 -day cycles until disease progression or discontin-uation due to toxicity. The study consisted of safety run- in (Part A) and expansion (Part B) periods. The primary endpoint was safety. Antitumor activity was an exploratory endpoint.Results: Sixteen patients were enrolled, 6 in Part A and 10 in Part B, and re-ceived a median of 4.0 treatment cycles. All patients were Asian; median age was 65.0 years. All patients experienced adverse events (AEs) related to cisplatin and 5- FU, and 8 (50.0%) patients experienced AEs related to durvalumab and treme-limumab. Grade =3 treatment-related AEs occurred in 7 (43.8%) patients. There were no deaths associated with AEs. Six (37.5%) patients achieved an objective response. Median progression- free survival was 3.75 months, and median overall survival was 9.69 months.Conclusions: Durvalumab with tremelimumab and chemotherapy demonstrated manageable safety and antitumor activity in patients with advanced or metastatic ESCC, warranting further investigation in randomized trials. Registered with ClinicalTrials.gov: NCT02658214. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | John Wiley & Sons Ltd. | - |
dc.relation.isPartOf | CANCER MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Cisplatin / adverse effects | - |
dc.subject.MESH | Esophageal Neoplasms* / drug therapy | - |
dc.subject.MESH | Esophageal Neoplasms* / etiology | - |
dc.subject.MESH | Esophageal Squamous Cell Carcinoma* / drug therapy | - |
dc.subject.MESH | Esophageal Squamous Cell Carcinoma* / etiology | - |
dc.subject.MESH | Fluorouracil / adverse effects | - |
dc.subject.MESH | Humans | - |
dc.title | Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Dae Ho Lee | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Bhumsuk Keam | - |
dc.contributor.googleauthor | Ken Kato | - |
dc.contributor.googleauthor | Yasutoshi Kuboki | - |
dc.contributor.googleauthor | Haiyan Gao | - |
dc.contributor.googleauthor | Alejandro Yovine | - |
dc.contributor.googleauthor | Scott H Robbins | - |
dc.contributor.googleauthor | Myung-Ju Ahn | - |
dc.identifier.doi | 10.1002/cam4.6260 | - |
dc.contributor.localId | A01166 | - |
dc.relation.journalcode | J00449 | - |
dc.identifier.eissn | 2045-7634 | - |
dc.identifier.pmid | 37489066 | - |
dc.subject.keyword | chemotherapy | - |
dc.subject.keyword | clinical trials | - |
dc.subject.keyword | esophageal squamous cell | - |
dc.subject.keyword | immunology | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | 김혜련 | - |
dc.citation.volume | 12 | - |
dc.citation.number | 15 | - |
dc.citation.startPage | 16066 | - |
dc.citation.endPage | 16075 | - |
dc.identifier.bibliographicCitation | CANCER MEDICINE, Vol.12(15) : 16066-16075, 2023-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.